Podoplanin Expression in Odontogenic Keratocysts Associated or not Associated With Nevoid Basal Cell Carcinoma Syndrome

被引:2
作者
Malaguez, Giulia G. [1 ]
Munhoz, Etiene A. [2 ]
Rivero, Elena R. C. [3 ]
Rados, Pantelis V. [1 ]
Oliveira, Marcia G. [1 ]
机构
[1] Univ Fed Rio Grande do Sul, Sch Dent, Dept Oral Pathol, Rua Ramiro Barcelos 2492 Sala 503, BR-90035003 Porto Alegre, RS, Brazil
[2] Univ Fed Santa Catarina, Sch Dent, Dept Stomatol, Florianopolis, SC, Brazil
[3] Univ Fed Santa Catarina, Sch Dent, Dept Pathol, Florianopolis, SC, Brazil
关键词
odontogenic keratocyst; nevoid basal cell carcinoma syndrome; orthokeratinized odontogenic cyst; podoplanin; ORAL-CANCER; TOOTH GERM; TUMORS; INVASION; EZRIN;
D O I
10.1097/PAI.0000000000000785
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Background: Podoplanin is a transmembrane glycoprotein expressed on various normal or neoplastic cells. Some studies have shown that podoplanin promotes the migration and invasion of tumor cells. This study evaluated a podoplanin expression in Odontogenic Keratocysts (OKs) associated or not associated with Nevoid Basal Cell Carcinoma Syndrome (NBCCS) and in Orthokeratinized Odontogenic Cysts (OOCs). Materials and Methods: A total of 50 lesions were obtained in this study, 28 OKs, 18 OKs associated with NBCCS, and 4 OOCs. Immunohistochemical expression of podoplanin in epithelial cells was evaluated using the following score: (a) intensity of immunostaining: (0: absent, 1: weak, 2: moderate, 3: strong, and 4: very strong) and (b) number of positively cells (0: 0%, 1: <25%, 2: 25% to 50%, 3: 50% to 75%, and 4: >75%). The final score was determined by adding the scores of a and b and ranged from 0 to 8 (0: absent, 1 to 4: weak, and 5 to 8: strong). Results: Podoplanin expression was significantly stronger in the basal layer OKs and NBCCS lesions. Further, podoplanin expression was the highest in the suprabasal layer of NBCCS lesions, followed by the suprabasal layers of OK and OOC lesions. Conclusions: Podoplanin expression is different in lesions of different biological behaviors. Podoplanin seems to play a role in cell proliferation and migration.
引用
收藏
页码:513 / 517
页数:5
相关论文
共 36 条
  • [1] [Anonymous], 2005, World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours
  • [2] Emerging role for ERM proteins in cell adhesion and migration
    Arpin, Monique
    Chirivino, Dafne
    Naba, Alexandra
    Zwaenepoel, Ingrid
    [J]. CELL ADHESION & MIGRATION, 2011, 5 (02) : 199 - 206
  • [3] Immunolocalization of podoplanin in benign odontogenic tumours with and without ectomesenchyme
    Caetano, Adriana dos Santos
    Tjioe, Kellen Cristine
    Sita Faustino, Simone Eloiza
    Costa Hanemann, Joao Adolfo
    Fernandes Belone, Andrea de Faria
    Soares, Cleverson Teixeira
    Oliveira, Denise Tostes
    [J]. ARCHIVES OF ORAL BIOLOGY, 2013, 58 (04) : 408 - 415
  • [4] Podoplanin expression in oral leukoplakia: Tumorigenic role
    Carlos de Vicente, Juan
    Pablo Rodrigo, Juan
    Rodriguez-Santamarta, Tania
    Lequerica-Fernandez, Paloma
    Allonca, Eva
    Maria Garcia-Pedrero, Juana
    [J]. ORAL ONCOLOGY, 2013, 49 (06) : 598 - 603
  • [5] A review of odontogenic keratocysts and the behavior of recurrences
    Chirapathomsakul, D
    Sastravaha, P
    Jansisyanont, P
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 2006, 101 (01): : 5 - 9
  • [6] Recurrence probability for keratocystic odontogenic tumors: An analysis of 6427 cases
    Chrcanovic, Bruno Ramos
    Gomez, Ricardo Santiago
    [J]. JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2017, 45 (02) : 244 - 251
  • [7] Are podoplanin and ezrin involved in the invasion process of the ameloblastomas?
    Costa, Y. F.
    Tjioe, K. C.
    Nonogaki, S.
    Soares, F. A.
    Lauris, J. R. Pereira
    Oliveira, D. Tostes
    [J]. EUROPEAN JOURNAL OF HISTOCHEMISTRY, 2015, 59 (01): : 39 - 44
  • [8] Podoplanin: a novel regulator of tumor invasion and metastasis
    Dang, Qi
    Liu, Jie
    Li, Juan
    Sun, Yuping
    [J]. MEDICAL ONCOLOGY, 2014, 31 (09) : 1 - 6
  • [9] DEEPA AG, 2017, J CLIN EXP DENT, V9, P1418
  • [10] El-Naggar AK, 2017, WHO CLASSIFICATION H, V4th